BRPI0811333A2 - "proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica" - Google Patents
"proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica"Info
- Publication number
- BRPI0811333A2 BRPI0811333A2 BRPI0811333-5A BRPI0811333A BRPI0811333A2 BR PI0811333 A2 BRPI0811333 A2 BR PI0811333A2 BR PI0811333 A BRPI0811333 A BR PI0811333A BR PI0811333 A2 BRPI0811333 A2 BR PI0811333A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- vector
- cell
- pharmaceutical composition
- dna sequence
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 2
- 102000037865 fusion proteins Human genes 0.000 title 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 title 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 title 1
- 101100425947 Mus musculus Tnfrsf13b gene Proteins 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- -1 cell Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH200710111162.2 | 2007-06-15 | ||
CN2007101111622A CN101323643B (zh) | 2007-06-15 | 2007-06-15 | 优化的TACI-Fc融合蛋白 |
PCT/CN2008/001162 WO2008154814A1 (en) | 2007-06-15 | 2008-06-16 | OPTIMIZED TACI-Fc FUSION PROTEINS |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0811333A2 true BRPI0811333A2 (pt) | 2015-06-16 |
BRPI0811333B1 BRPI0811333B1 (pt) | 2020-09-15 |
BRPI0811333B8 BRPI0811333B8 (pt) | 2021-05-25 |
Family
ID=40155884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0811333A BRPI0811333B8 (pt) | 2007-06-15 | 2008-06-16 | proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica |
Country Status (8)
Country | Link |
---|---|
US (1) | US8193316B2 (pt) |
EP (1) | EP2161287B1 (pt) |
JP (1) | JP5372917B2 (pt) |
KR (1) | KR101204229B1 (pt) |
CN (1) | CN101323643B (pt) |
BR (1) | BRPI0811333B8 (pt) |
RU (1) | RU2433141C2 (pt) |
WO (1) | WO2008154814A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201120210A (en) | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
IN2013MN01394A (pt) * | 2011-01-06 | 2015-06-12 | Complix Nv | |
CN102085368B (zh) * | 2011-01-19 | 2013-06-12 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
CN102085367B (zh) * | 2011-01-19 | 2012-08-22 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用 |
CN103833856B (zh) * | 2012-11-22 | 2017-05-03 | 上海康岱生物医药技术股份有限公司 | 抑制taci‑baff复合物形成的融合蛋白及其制法和用途 |
CN103936833B (zh) * | 2014-04-18 | 2016-02-10 | 天津大学 | BLyS拮抗肽、含TC-Fc融合蛋白基因的质粒及TC-Fc融合蛋白 |
WO2018236995A2 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS |
CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
BR112021025458A2 (pt) * | 2019-12-10 | 2022-06-21 | Remegen Co Ltd | Formulação farmacêutica, método de preparação e uso da mesma |
JP2022539785A (ja) | 2019-12-24 | 2022-09-13 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質及びその用途 |
AU2021268033A1 (en) | 2020-05-08 | 2022-12-15 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof |
CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
CA3237992A1 (en) * | 2021-03-31 | 2022-10-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Truncated taci polypeptide and fusion protein and use thereof |
EP4333869A1 (en) | 2021-05-07 | 2024-03-13 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
WO2022258045A1 (zh) * | 2021-06-11 | 2022-12-15 | 山东先声生物制药有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
BR112023018745A2 (pt) | 2021-08-10 | 2024-03-12 | Remegen Co Ltd | Método para tratar nefropatia por iga com proteína de fusão de taci-fc |
CN117916273A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
JP2024512935A (ja) | 2021-09-30 | 2024-03-21 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質を用いたシェーグレン症候群の治療方法 |
TW202334225A (zh) * | 2021-11-11 | 2023-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗icosl抗體融合蛋白及用途 |
CA3236667A1 (en) | 2022-06-08 | 2023-12-14 | Jianmin Fang | Method for treating myasthenia gravis with taci-fc fusion protein |
WO2024046301A1 (zh) * | 2022-08-29 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 包含taci多肽的融合蛋白及其用途 |
WO2024067756A1 (zh) * | 2022-09-30 | 2024-04-04 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗膜性肾病的方法 |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
WO2024114777A1 (zh) * | 2022-12-02 | 2024-06-06 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗微小病变型肾病的方法 |
WO2024120458A1 (zh) * | 2022-12-07 | 2024-06-13 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白液体药物制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001253920B2 (en) * | 2000-04-27 | 2006-03-16 | Apoxis Sa | Use of taci as an anti-tumor agent |
KR20040030628A (ko) * | 2001-05-24 | 2004-04-09 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
MX2007005378A (es) * | 2004-11-04 | 2008-02-14 | Genentech Inc | Polipeptidos que ligan a baff y/o april. |
EP1922079A2 (en) * | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
CN100471872C (zh) * | 2005-11-04 | 2009-03-25 | 余波 | 包含vegf受体片段的优化融合蛋白质及其医疗应用 |
-
2007
- 2007-06-15 CN CN2007101111622A patent/CN101323643B/zh active Active
-
2008
- 2008-06-16 EP EP08757443.0A patent/EP2161287B1/en active Active
- 2008-06-16 RU RU2009148020/10A patent/RU2433141C2/ru active
- 2008-06-16 JP JP2010511477A patent/JP5372917B2/ja active Active
- 2008-06-16 KR KR1020097026657A patent/KR101204229B1/ko active IP Right Grant
- 2008-06-16 BR BRPI0811333A patent/BRPI0811333B8/pt active IP Right Grant
- 2008-06-16 WO PCT/CN2008/001162 patent/WO2008154814A1/zh active Application Filing
-
2009
- 2009-12-15 US US12/638,392 patent/US8193316B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2161287A1 (en) | 2010-03-10 |
CN101323643A (zh) | 2008-12-17 |
WO2008154814A1 (en) | 2008-12-24 |
KR101204229B1 (ko) | 2012-11-26 |
JP2010529967A (ja) | 2010-09-02 |
BRPI0811333B8 (pt) | 2021-05-25 |
EP2161287A4 (en) | 2010-08-11 |
BRPI0811333B1 (pt) | 2020-09-15 |
US8193316B2 (en) | 2012-06-05 |
JP5372917B2 (ja) | 2013-12-18 |
RU2433141C2 (ru) | 2011-11-10 |
EP2161287B1 (en) | 2015-03-04 |
KR20100009600A (ko) | 2010-01-27 |
US20100136008A1 (en) | 2010-06-03 |
RU2009148020A (ru) | 2011-07-10 |
CN101323643B (zh) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0811333A2 (pt) | "proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica" | |
BRPI0807480A2 (pt) | Ligando, imunoglobulina g, composição e proteína de fusão | |
IL202443B (en) | Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid | |
BRPI0716416A2 (pt) | polipeptídeo substancialmente puro entre 37 e 47 besíduos de aminoácido de comprimento, ácido nucléico isolado, vetor: célula hospedeira e composição farmacêutica | |
IL187168A (en) | Proteins or polypeptides containing two identical nanobedis against Factor von Willebrand, methods for their preparation, medicinal preparations containing them and their use | |
NL2000626A1 (nl) | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. | |
BRPI0810305A2 (pt) | "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição" | |
HK1191959A1 (zh) | 免疫球蛋白融合蛋白 | |
BRPI0812400A2 (pt) | Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade. | |
BRPI0814296A2 (pt) | Polipeptídeo isolado, seqüência de nucleotídeos, vetor, célula hospedeira, e, uso do polipeptídeo, da seqüência de nucleotídeos, do vetor ou da célula hospedeira | |
WO2006076594A3 (en) | Antibodies and fc fusion proteins with altered immunogenicity | |
EP2000483A4 (en) | VEGF RECEPTOR FUSION PROTEIN AND APPLICATION THEREOF | |
BRPI0806501A2 (pt) | Proteína de fusão, molécula de ácido nucleico, vetor, célula hospedeira, vacina ou composição imunogênica, e, uso da proteína de fusão. | |
BRPI0820270A2 (pt) | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. | |
BRPI0821447A2 (pt) | Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea | |
DE602005008893D1 (de) | Brennstoffzellenstapel und diesen enthaltendes Brennstoffzellensystem | |
BRPI0716744A2 (pt) | proteínas de fusão de albumina | |
DK2064334T3 (da) | Aldehydtags, anvendelser deraf i site-specifik proteinmodificering | |
IL204607A0 (en) | Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof | |
BRPI1006368A2 (pt) | proteína de fusão. molécula de ácido nucleico, vetor, célula modificada geneticamente, método para produção da proteína de fusão, usos da proteína de fusão, composição, método para preparação de uma composição, kits, método e uso da proteína de fusão | |
PL2007884T3 (pl) | Białka fuzyjne celulazy i ich zastosowanie | |
EP2086576B8 (en) | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use | |
BR112012001977A2 (pt) | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar. | |
WO2010014922A3 (en) | Protein purification tags and uses thereof | |
BRPI0813743A2 (pt) | Método para produzir trombina humana recombinante, trombina recombinante, composição farmacêutica, sequência de dna isolada, vetor, sequência de aminoácido, e, célula hospedeira. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |